Precigenjp Morgan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article GERMANTOWN, Md., Jan. 13, 2021 /PRNewswire/  Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual J.P. Morgan Healthcare Conference.  Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2020 clinical achievements and set forth Precigen s clinical goals for 2021. In addition to reviewing the latest clinical updates for Precigen s PRGN-3005 UltraCAR-T, PRGN-3006 UltraCAR-T, AG019 ActoBiotics™, the presentation included the following additional announcements: UltraCAR-T Library Approach: Precigen introduced the Company s vision for a new UltraCAR-T library approach to transform the personalized cell therapy landscape for cancer patients. Precigen s goal is to develop and validate a library of non-viral plasmids to target tumor-associated an

United statesPrecigenjp morganSteven harasymPrecigen ultravectorHelen sabzevariDevelopment agreementCenters for diseaseNational cancer instituteNational institutes of healthUs centers for diseaseWorld health organizationDrug administrationExchange commissionUltracart libraryPrecigen incCooperative research